ReviewBJR open2025
Imaging patterns and recommendations for diagnosis, staging, and management of lung cancer.
Review in BJR open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between preoperative inflammatory biomarkers and postoperative pulmonary complications in stage I-II non-small cell lung cancer: a retrospective study.Frontiers in medicine · 2026Article
- Pre-treatment inflammatory markers can identify the risk of immune-related toxicity in non-small cell lung cancer patients receiving immune checkpoint inhibitor therapy.Frontiers in oncology · 2026Article
- Probable Pleural-Based Pulmonary Tuberculoma Mimicking Lung Malignancy: A Case Report.Clinical medicine insights. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the second most commonly diagnosed cancer worldwide. In the present era of targeted therapy for various lung cancer mutations, it is essential to be aware of the imaging correlates of various lung cancer mutations on contrast enhanced computed tomography of thorax. In this article, we have discussed the imaging patterns of various types of lung cancer including different mutations and also comprehensively reviewed the imaging recommendations (National Comprehensive Cancer Network [NCCN], European Society of Medical Oncology [ESMO] and American Society of Clinical Oncology [ASCO]) and management guidelines of lung cancer (non-small cell, small cell and other neuroendocrine tumours). We have also discussed guidelines for screening, diagnosis, staging (recent 9th edition tumour node metastasis [TNM]), treatment response evaluation, and follow up. Role of interventional radiology in the treatment of primary lung cancer, lung metastasis, and management of posttreatment complications, have also been described in detail in this article. In addition, current status of artificial intelligence in lung cancer has also been briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.